|Articles|November 1, 2013
- Applied Clinical Trials-11-01-2013
- Volume 22
- Issue 11
Applied Clinical Trials Digital Edition - November 2013
Regulatory: Successful Phase III Trial Monitoring Trial Design: Multi-regional Trials Data Evaluation Also in this issue: Compromise in Europe's Rule Debate True Potential of Adaptive Trial Designs Bring Your Own Device
Advertisement
Articles in this issue
almost 13 years ago
Sponsors Struggle with Data Disclosure Requirementsalmost 13 years ago
Evaluation of Data for Multi-Regional Trials: A Three-Layer Approachalmost 13 years ago
Cost Per Visit Trends Higher for Less Established Regionsalmost 13 years ago
Modeling Successful Phase III Trialsalmost 13 years ago
GCP's Future: Looking Ahead to the Next 20 Yearsalmost 13 years ago
Crunch-Time for Europe's Clinical Trials Rulesalmost 13 years ago
Device Independence is the Future of Clinical Trialsalmost 13 years ago
Business and People November 2013almost 13 years ago
Adoption of Adaptive Trial Designs Poised to AccelerateAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
$500,000 Lost a Day: The Economics of Clinical Trial Execution Is Pharma's Expensive Secret
2
ACT Brief: Trial Execution Cost Burden and Protocol Variability, Real-World Oncology Data Curation Complexity, and Real-Time Analytics Datapoint Scale
3
Bridging Data Gaps: Curating Real-World Data for Oncology Research
4
Why Execution Strategy Begins at the Business Decision: Q&A with Elizabeth Walsh, Walsh Clinical Advisory
5